| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer | Phase 1 / Phase 2 | 2025-04-18 |
| Active Not Recruiting | INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Phase 3 | 2023-12-11 |
| Completed | Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects Healthy Subjects | Phase 1 | 2022-01-12 |
| Terminated | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS ALS | Phase 3 | 2022-01-11 |
| Completed | Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injur Spinal Cord Injury | Phase 2 | 2021-08-27 |
| Recruiting | Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoi EPP, XLP | Phase 3 | 2021-08-10 |
| Completed | Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects Healthy Subjects | Phase 1 | 2021-03-23 |
| Completed | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sc Diffuse Cutaneous Systemic Sclerosis | Phase 2 | 2021-02-05 |
| Completed | PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Renal Impairment, Normal Renal Function | Phase 1 | 2020-12-02 |
| Terminated | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS ALS | Phase 3 | 2020-11-13 |
| Completed | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | 2020-10-29 |
| Completed | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria EPP, XLP | Phase 3 | 2020-06-01 |
| Completed | Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury Spinal Cord Injury | Phase 1 | 2020-04-19 |
| Completed | Safety Study of Oral Edaravone Administered in Subjects With ALS ALS | Phase 3 | 2019-11-18 |
| Unknown | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) Amyotrophic Lateral Sclerosis, ALS | — | 2019-10-21 |
| Completed | Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hep Mild and Moderate Hepatic Impairment | Phase 1 | 2019-08-01 |
| Terminated | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects Healthy | Phase 1 | 2019-01-15 |
| Completed | Safety and Efficacy Study of MT-2990 in Women With Endometriosis Endometrial Related Pain | Phase 2 | 2019-01-15 |
| Completed | Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor Healthy Volunteer | Phase 1 | 2018-10-25 |
| Completed | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria Erythropoietic Protoporphyria (EPP) | Phase 2 | 2018-07-05 |
| Completed | Definitive QT Study With MT-8554 Healthy Volunteer | Phase 1 | 2018-04-23 |
| Completed | Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms Vasomotor Symptoms (VMS) | Phase 2 | 2018-04-18 |
| Completed | Mass Balance Study With MT-7117 Healthy Volunteer | Phase 1 | 2018-03-23 |
| Completed | Mass Balance Study With MT-8554 Healthy Volunteer | Phase 1 | 2017-12-19 |
| Completed | MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women Menopause Hot Flashes | Phase 2 | 2017-10-09 |